What is CoMentis?
CoMentis, Inc. is dedicated to the research and development of small molecule drugs targeting central nervous system (CNS) disorders. Headquartered in South San Francisco, the company's foundation is built upon pioneering discoveries related to the beta-secretase enzyme. CoMentis is developing an orally administered, disease-modifying treatment for Alzheimer's disease designed to inhibit the beta-secretase enzyme. This mechanism aims to reduce the formation of beta-amyloid peptides, thereby mitigating the deleterious effects of their accumulation and subsequent pathologies, which are implicated in Alzheimer's disease progression. The company is actively pursuing the development of these beta-secretase inhibitor drugs, notably through a collaboration agreement initiated in 2008 with Astellas Pharma, Inc.
How much funding has CoMentis raised?
CoMentis has raised a total of $93.5M across 5 funding rounds:
Series A
$7M
Series B
$50M
Series C
$12M
Series D
$20M
Series E
$4.5M
Series A (2005): $7M, investors not publicly disclosed
Series B (2006): $50M, investors not publicly disclosed
Series C (2007): $12M, investors not publicly disclosed
Series D (2008): $20M featuring Clarus Ventures, Index Ventures III, Sanderling Venture Partners, and Astellus Pharma
Series E (2016): $4.5M backed by Clarus Ventures and Sanderling Ventures
Key Investors in CoMentis
Clarus Ventures
Clarus Ventures is a venture capital firm that invests in early-stage and growth-stage companies within the life sciences sector, focusing on therapeutics, diagnostics, and medical devices. They aim to support innovative companies with strong scientific foundations and significant market potential.
Sanderling Ventures
Sanderling Ventures is a venture capital firm with a long history in the biomedical industry, specializing in building and financing new companies. They focus on early-stage investments across various life science domains, including small molecule therapeutics and platform technologies.
Astellas Pharma
Astellas Pharma is a global pharmaceutical company dedicated to improving the health of people worldwide through the development of innovative medicines. Their involvement suggests a strategic interest in CoMentis's therapeutic area and potential for future collaboration or acquisition.
What's next for CoMentis?
The recent strategic investment in CoMentis signals a pivotal phase for the company, likely enabling accelerated clinical trials and further pipeline expansion. With a focus on Alzheimer's disease, a condition with significant unmet medical needs, CoMentis is positioned to leverage this capital for substantial growth. Future developments may include strategic partnerships, expanded research into other CNS disorders, and progression towards regulatory submissions. The company's commitment to innovative small molecule drug development, supported by substantial backing, suggests a trajectory aimed at bringing novel therapies to patients.
See full CoMentis company page
